Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

被引:94
作者
Douglas, SA [1 ]
机构
[1] GlaxoSmithKline, Cardiol & Urogenital Ctr Excellence Drug Discover, King Of Prussia, PA 19406 USA
关键词
D O I
10.1016/S1471-4892(03)00012-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Urotensin-II (U-II), originally identified as a fish neuropeptide, exerts a broad spectrum of biological actions in mammals: responses that influence cardiorenal, pulmonary (bronchoconstriction), central nervous system (locomotion) and endocrine (thyroid-stimulating hormone, prolactin and insulin secretion) function. Because the U-II isopeptide family is highly conserved across species, both amongst invertebrates and vertebrates, it has been inferred that U-II and its G-protein-coupled receptor, UT, play a seminal role in the physiological regulation of major mammalian organ systems, most notably within the cardiovasculature. However, despite the evolutionary conservation of U-II, the (patho)physiological significance of this 'somatostatin-like' peptide remains ambiguous. Can the identification of a fish peptide as a ligand for an 'orphan' mammalian G-protein-coupled receptor really tell us something about human physiology? Emerging preclinical and clinical data suggest that it might.
引用
收藏
页码:159 / 167
页数:9
相关论文
共 43 条
[1]  
AISSAOUI H, 2002, Patent No. 200276979
[2]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[3]   Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist [J].
Behm, DJ ;
Herold, CL ;
Ohlstein, EH ;
Knight, SD ;
Dhanak, D ;
Douglas, SA .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (04) :449-458
[4]  
BEHM DJ, 2000, PHARMACOLOGIST, V44, P173
[5]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[6]  
Bowman W.C., 1980, TXB PHARM, V2nd
[7]   Effects of human urotensin II in isolated vessels of various species;: comparison with other vasoactive agents [J].
Camarda, V ;
Rizzi, A ;
Calò, G ;
Gendron, G ;
Perron, SI ;
Kostenis, E ;
Zamboni, P ;
Mascoli, F ;
Regoli, D .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (02) :141-149
[8]  
COY DH, 2000, REGUL PEPTIDES, V94, pA48
[9]   Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chloropheny)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954) [J].
Croston, GE ;
Olsson, R ;
Currier, EA ;
Burstein, ES ;
Weiner, D ;
Nash, N ;
Severance, D ;
Allenmark, SG ;
Thunberg, L ;
Ma, JN ;
Mohell, N ;
O'Dowd, B ;
Brann, MR ;
Hacksell, U .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) :4950-4953
[10]   Congestive heart failure and expression of myocardial urotensin II [J].
Douglas, SA ;
Tayara, L ;
Ohlstein, EH ;
Halawa, N ;
Giaid, A .
LANCET, 2002, 359 (9322) :1990-1997